Jam

  • Sinclair Launches Sinclair Cares to Fight Cancer, Partnering with American Cancer Society

    Sinclair Broadcast Group is partnering with the American Cancer Society for “Sinclair Cares: Help Drive Out Cancer,” a campaign running July 14-27. It aims to raise awareness and support for ACS’s Road To Recovery®, providing free rides to cancer treatment. Sinclair stations will broadcast content, including a special on July 26th and 27th featuring volunteer drivers and patients. The campaign encourages volunteering, donations, and seeking help through SinclairCares.com, leveraging Sinclair’s reach to address transportation challenges faced by cancer patients.

    2025年7月14日
  • Orbec Drills Over 2,000 Meters at Muus Gold Property in Chibougamau, Quebec

    Mines d’Or Orbec (BLUE) completed a 2,000+ meter drilling campaign at its Muus property in Quebec’s Abitibi Greenstone Belt, focusing on the Lac Bernard area. Drill holes intersected silicified and pyrite-bearing zones, geological indicators of gold mineralization. The property is near IAMGOLD’s Nelligan Deposit. The company awaits assay results in approximately 6 weeks. Additionally, Orbec granted stock options for 4,150,000 common shares at $0.06 per share, expiring July 11, 2030.

    2025年7月14日
  • Battery Mineral Resources Reports Q1 2025 Financial Results, Appoints Keith Spano to Board and Audit Committee

    Battery Mineral Resources (BTRMF) filed its Q1 2025 financials on SEDAR+ (July 11, 2025) and anticipates trading to resume around July 15, 2025, pending cease trade order revocation. Keith Spano was appointed to the Board of Directors and as Head of the Audit Committee, replacing Joe Tuso in that role (Tuso remains a Director). Spano brings financial and audit experience from Yorktown Partners. The company focuses on copper production and has projects including the Punitaqui Mining Complex in Chile.

    2025年7月14日
  • Waters and BD Biosciences & Diagnostic Solutions to Merge, Forming a Regulated Testing Leader

    Waters Corporation and BD (Becton, Dickinson and Company) have announced a definitive agreement to merge BD’s Biosciences & Diagnostic Solutions business with Waters, creating a leading life science and diagnostics company. The deal, valued at $17.5 billion structured as a Reverse Morris Trust, is expected to double Waters’ addressable market to $40 billion and generate $345 million in annualized EBITDA synergies by 2030.The combined company anticipates approximately $6.5 billion in 2025 sales and mid-teens adjusted EPS growth over five years, with the transaction boosting adjusted EPS within the first year.

    2025年7月14日
  • Himax & Rabboni Announce Scalable Multi-Scenario Endpoint AI Sensing System for Wearable Devices

    Himax Technologies and Rabboni are collaborating to launch bboni Ai, a multi-scenario endpoint AI sensing system for wearables. It combines Rabboni’s high-precision IMU motion sensors with Himax’s ultra-low power WiseEye2 AI processor, enabling real-time on-device AI processing. Applications span smart healthcare, sports technology, and education. Himax will launch the bboni Ai Developer Program in late-July 2025, offering APIs and SDKs. The system enhances data privacy, reduces latency, and enables real-time AI inference while minimizing power consumption.

    2025年7月14日
  • Ellomay Capital Announces Proposed Private Placement

    Ellomay Capital (ELLO) announced a private placement of 926,000 shares to Israeli investors at NIS 54 per share, expecting NIS 50 million gross proceeds. Menora Mivtachim will acquire approximately 6% ownership. Closing is expected in July 2025, pending regulatory approval. Proceeds will be used for general corporate purposes. The placement offers a slight discount to recent trading prices. Existing shareholders may experience dilution.

    2025年7月13日
  • Global Property Expo: Your Gateway to International Homes in Singapore

    The Global Property Expo, organized by JLL, will be held at the Sands Expo & Convention Centre in Singapore from July 18-20, 2025. This event provides Singaporeans with opportunities to explore international residential properties from over 20 countries. Attendees can access expert-led talks and connect with developers, legal advisors, and mortgage specialists. The expo aims to equip buyers with the knowledge and resources needed for overseas property investment, including insights into market trends, financing, and legal considerations, and residency implications.

    2025年7月13日
  • Accelerated Tolmer Soil Sampling Analysis: 1.9 km² Area

    Barton Gold Holdings (OTCQB:BGDFF) completed soil sampling across 1.9km² at its Tarcoola Gold Project’s Tolmer silver discovery, following an expanded RC drilling program. Approximately 380 samples were collected, with results expected in September 2025. The sampling aims to identify a larger mineralized footprint, building upon previously discovered high-grade silver mineralization, including assays up to 4,747 g/t Ag. The Tolmer project is considered a potential high-risk, high-reward venture.

    2025年7月13日
  • Ki Corporation and Public Storage Update Offer to Acquire Abacus Storage King

    Ki Corporation and Public Storage, operating as a Consortium, have made a revised non-binding offer to acquire Abacus Storage King for A$1.65 per security. Both parties agreed to due diligence, signaling progress. Public Storage sees growth potential in the Australian self-storage market. The deal is non-binding and subject to conditions, including regulatory and securityholder approval. Public Storage will not provide further updates unless a definitive agreement is reached.

    2025年7月13日
  • Amylyx Pharmaceuticals Presents Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025

    Amylyx Pharmaceuticals presented new data on avexitide, a GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH), at ENDO 2025. A Phase 2b trial showed avexitide 90mg daily significantly reduced hypoglycemic events. Population PK/PD data confirmed sustained therapeutic exposure for 24 hours. The Phase 3 LUCIDITY trial evaluating this dose is underway, with recruitment expected to complete in 2025 and topline data anticipated in H1 2026. Avexitide has FDA Breakthrough Therapy designation for PBH.

    2025年7月13日